7 results on '"Gao, Xiao-Ning"'
Search Results
2. Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia.
- Author
-
Gao, Xiao-Ning, Su, Yong-Feng, Li, Meng-yue, Jing, Yu, Wang, Jun, Xu, Lei, Zhang, Lin-Lin, Wang, An, Wang, Yi-Zhi, Zheng, Xuan, Li, Yan-Fen, and Liu, Dai-Hong
- Subjects
- *
DECITABINE , *ACUTE myeloid leukemia , *DRUG side effects , *PROGRAMMED cell death 1 receptors , *LUNG infections , *DNA , *T cells - Abstract
Anti-PD-1 monotherapy had limited clinical efficacy in relapsed/refractory (r/r) AML patients with higher PD-1 and PD-L1 expression. Hence, we investigated the efficacy and safety of PD-1 inhibitor with DNA hypomethylating agent (HMA) + CAG regimen in patients who had failed prior AML therapy. In this phase 2, single-arm study, r/r AML patients received azacitidine or decitabine plus CAG regimen with tislelizumab. Primary endpoints were efficacy (objective response rate [ORR]) and safety. Secondary endpoints included overall survival (OS), event-free survival (EFS) and duration of response (DOR). Statistical analyses were performed using Stata 14.0 and SPSS 20.0 software where P < 0.05 denoted significance. Twenty-seven patients were enrolled patients and completed 1 cycle, and 14 (51.9%) and 4 (14.8%) patients completed 2 and 3 cycles, respectively. ORR was 63% (14: complete remission [CR]/CR with incomplete hematologic recovery [CRi], 3: partial remission (PR), 10: no response [NR]). Median OS (mOS) and EFS were 9.7 and 9.2 months, respectively. With a median follow-up of 8.2 months (1.1–26.9), the mOS was not reached in responders (CR/CRi/PR) while it was 2.4 months (0.0–5.4) in nonresponders (P = 0.002). Grade 2–3 immune-related adverse events (irAEs) were observed in 4 (14.8%) patients and 3 nonresponders died of lung infection after treatment. Tislelizumab + HMA + CAG regimen showed improved outcomes in r/r AML patients with lower pretherapy leukemia burden. irAEs were mild and low-grade and higher pretherapy bone marrow CD4+ CD127+ PD-1+ T cells might serve as a predictor of treatment response. ClinicalTrials.gov identifier NCT04541277. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next‐generation sequencing technique.
- Author
-
Wang, Rui‐Qi, Chen, Chong‐Jian, Jing, Yu, Qin, Jia‐Yue, Li, Yan, Chen, Guo‐Feng, Zhou, Wei, Li, Yong‐Hui, Wang, Juan, Li, Da‐Wei, Zhao, Hong‐Mei, Wang, Bian‐Hong, Wang, Li‐Li, Wang, Hong, Wang, Meng‐Zhen, Gao, Xiao‐Ning, and Yu, Li
- Subjects
ACUTE myeloid leukemia ,NUCLEOTIDE sequencing ,GENETIC mutation ,PROGNOSIS ,UNIVARIATE analysis ,PRELEUKEMIA ,DISEASE remission - Abstract
To explore the characteristics and prognostic significance of genetic mutations in acute myeloid leukemia (AML), we screened the gene mutation profile of 171 previously untreated AML patients using a next‐generation sequencing technique targeting 127 genes with potential prognostic significance. A total of 390 genetic alterations were identified in 149 patients with a frequency of 87.1%. Younger age and high sensitivity to induction chemotherapy were associated with a lower number of mutations. NPM1 mutation was closely related to DNMT3A and FLT3‐internal tandem duplication (FLT3‐ITD) mutations, but mutually exclusive with ASXL1 mutation and CEBPAdouble mutation. In univariate analysis, ASXL1 or TET2 mutation predicted shorter overall survival (OS) or relapse‐free survival (RFS), DNMT3A, FLT3‐ITD, or RUNX1 mutation predicted a higher likelihood of remission‐induction failure, whereas NRAS mutation or CEBPAdouble mutation predicted longer OS. Concurrent DNMT3A, FLT3‐ITD, and NPM1 mutations predicted shorter OS. Hypomethylation agents could improve the OS in patients with DNA methylation‐related mutations. According to multivariate analysis, TET2 mutation was recognized as an independent prognostic factors for RFS. In summary, our study provided a detailed pattern of gene mutations and their prognostic relevance in Chinese AML patients based on targeted next‐generation sequencing screening. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. Comparison of Clinical Efficacy of Cytarabine with Different Regimens in Postremission Consolidation Therapy for Adult t(8;21) AML Patients: A Multicenter Retrospective Study in China.
- Author
-
Gong, Dan, Li, Wei, Hu, Liang-Ding, Shen, Jian-Liang, Fang, Mei-Yun, Yang, Qing-Ming, Wang, Heng-Xiang, Ke, Xiao-Yan, Chen, Hui-Ren, Wang, Zhao, Liu, Hui, Liu, Feng, Ma, Yi-Gai, Wang, Jing-Wen, Li, Hong-Hua, Wang, Quan-Shun, Jing, Yu, Gao, Xiao-Ning, Dou, Li-Ping, and Li, Yong-Hui
- Subjects
ACUTE myeloid leukemia treatment ,CYTARABINE ,DRUG efficacy ,DISEASES in adults ,RETROSPECTIVE studies - Abstract
Background: The survival of patients with acute myeloid leukemia (AML) with t(8;21) was reported to be shorter in China than in other countries. Patients: We analyzed the correlation between different cytarabine (Ara-c) regimens and outcome in 255 t(8;21) AML patients in China who received postremission consolidation chemotherapy only. Results: The 5-year overall survival (OS) of the high-dose Ara-c group (HDAC; 2≤ Ara-c ≤3 g/m
2 ), intermediate-dose Ara-c group (MDAC; 1.0≤ Ara-c <2.0 g/m2 ), low-dose Ara-c group (LDAC; 0.2< Ara-c <1.0 g/m2 ) and standard-dose Ara-c group (SDAC; 0.1≤ Ara-c ≤0.2 g/m2 ) were 65.3, 39.4, 25.2 and 27.9%, respectively (p = 0.003). In the HDAC group, but not in the MDAC group, the 5-year OS of patients who achieved 3-4 cycles of chemotherapy was superior to those who underwent 1-2 cycles (84.4 vs. 43.6%, p < 0.05), and the 3-year OS of patients who achieved an accumulated 36 g/m2 of Ara-c was significantly higher compared to those who did not (85.3 vs. 39.2%, p < 0.05). Multivariate analysis indicated that factors such as WBC >3.5 × 109 /l, PLT ≤30 × 109 /l, and extramedullary infiltration were associated with a poor prognosis. Conclusion: The survival of t(8;21) AML patients treated with high-dose Ara-c (≥2 g/m2 ) was superior to other dose levels in postremission consolidation chemotherapy. Patient survival was improved by 3-4 cycles of chemotherapy with an accumulated concentration of 36 g/m2 of Ara-c. WBC >3.5 × 109 /l, PLT ≤30 × 109 /l and extramedullary infiltration could be indicative of a poor clinical prognosis. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
5. Low Dose Decitabine Treatment Induces CD80 Expression in Cancer Cells and Stimulates Tumor Specific Cytotoxic T Lymphocyte Responses
- Author
-
Wang, Li-Xin, Mei, Zhen-Yang, Zhou, Ji-Hao, Yao, Yu-Shi, Li, Yong-Hui, Xu, Yi-Han, Li, Jing-Xin, Gao, Xiao-Ning, Zhou, Min-Hang, Jiang, Meng-Meng, Gao, Li, Ding, Yi, Lu, Xue-Chun, Shi, Jin-Long, Luo, Xu-Feng, Wang, Jia, Wang, Li-Li, Qu, Chunfeng, Bai, Xue-Feng, and Yu, Li
- Subjects
DRUG dosage ,GENE expression ,CD80 antigen ,CANCER cells ,CYTOTOXIC T cells ,IMMUNOGENETICS ,DECITABINE - Abstract
Lack of immunogenicity of cancer cells has been considered a major reason for their failure in induction of a tumor specific T cell response. In this paper, we present evidence that decitabine (DAC), a DNA methylation inhibitor that is currently used for the treatment of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and other malignant neoplasms, is capable of eliciting an anti-tumor cytotoxic T lymphocyte (CTL) response in mouse EL4 tumor model. C57BL/6 mice with established EL4 tumors were treated with DAC (1.0 mg/kg body weight) once daily for 5 days. We found that DAC treatment resulted in infiltration of IFN-γ producing T lymphocytes into tumors and caused tumor rejection. Depletion of CD8
+ , but not CD4+ T cells resumed tumor growth. DAC-induced CTL response appeared to be elicited by the induction of CD80 expression on tumor cells. Epigenetic evidence suggests that DAC induces CD80 expression in EL4 cells via demethylation of CpG dinucleotide sites in the promoter of CD80 gene. In addition, we also showed that a transient, low-dose DAC treatment can induce CD80 gene expression in a variety of human cancer cells. This study provides the first evidence that epigenetic modulation can induce the expression of a major T cell co-stimulatory molecule on cancer cells, which can overcome immune tolerance, and induce an efficient anti-tumor CTL response. The results have important implications in designing DAC-based cancer immunotherapy. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
6. A Histone Acetyltransferase p300 Inhibitor C646 Induces Cell Cycle Arrest and Apoptosis Selectively in AML1-ETO-Positive AML Cells.
- Author
-
Gao, Xiao-ning, Lin, Ji, Ning, Qiao-yang, Gao, Li, Yao, Yu-shi, Zhou, Ji-hao, Li, Yong-hui, Wang, Li-li, and Yu, Li
- Subjects
- *
HISTONE acetyltransferase , *CELL cycle , *APOPTOSIS , *ACUTE myeloid leukemia , *CANCER cells , *CHIMERIC proteins , *GENE expression , *MOLECULAR biology , *CANCER treatment - Abstract
AML1-ETO fusion protein (AE) is generated by t(8;21)(q22;q22) chromosomal translocation, which is one of the most frequently observed structural abnormalities in acute myeloid leukemia (AML) and displays a pivotal role in leukemogenesis. The histone acetyltransferase p300 promotes self-renewal of leukemia cells by acetylating AE and facilitating its downstream gene expression as a transcriptional coactivator, suggesting that p300 may be a potential therapeutic target for AE-positive AML. However, the effects of p300 inhibitors on leukemia cells and the underlying mechanisms have not been extensively investigated. In the current study, we analyzed the anti-leukemia effects of C646, a selective and competitive p300 inhibitor, on AML cells. Results showed that C646 inhibited cellular proliferation, reduced colony formation, evoked partial cell cycle arrest in G1 phase, and induced apoptosis in AE-positive AML cell lines and primary blasts isolated from leukemic mice and AML patients. Nevertheless, no significant inhibitory effects were observed in granulocyte colony-stimulating factor-mobilized normal peripheral blood stem cells. Notably, AE-positive AML cells were more sensitive to lower C646 doses than AE-negative ones. And C646-induced growth inhibition on AE-positive AML cells was associated with reduced global histone H3 acetylation and declined c-kit and bcl-2 levels. Therefore, C646 may be a potential candidate for treating AE-positive AML. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
7. MicroRNA-193b regulates c-Kit proto-oncogene and represses cell proliferation in acute myeloid leukemia
- Author
-
Gao, Xiao-ning, Lin, Ji, Gao, Li, Li, Yong-hui, Wang, Li-li, and Yu, Li
- Subjects
- *
NON-coding RNA , *GENETIC regulation , *PROTO-oncogenes , *CANCER cell proliferation , *ACUTE myeloid leukemia , *GENETIC mutation , *HEALTH outcome assessment , *LEUKEMIA etiology - Abstract
Abstract: Mutations and/or overexpression of c-Kit proto-oncogene frequently occur in subsets of acute myeloid leukemia (AML) and contribute to abnormal cell proliferation and poor outcomes. We showed that c-Kit expression was subject to post-transcriptional regulation by microRNA (miRNA)-193b. Notably, miR-193b was significantly down-regulated in the examined AML cells and its levels were inversely correlated with c-Kit levels. Restoration of miR-193b expression in AML cells resulted in distinctly reduced c-Kit expression and inhibited cell growth. These data reveal a role for miR-193b dysregulation in myeloid leukemogenesis and the therapeutic promise of regulating miR-193b expression for c-Kit-positive AML. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.